Singh Nandini, Yadav Hariom, Marotta Francesco, Singh Vinod
Department of Microbiology, Barkatullah University, Bhopal, Madhya Pradesh, INDIA.
Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Int J Probiotics Prebiotics. 2017;12(2):57-68. Epub 2017 Aug 21.
Spondyloarthropathy (SpA) or spondyloarthrosis refers to any joint disease of the vertebral column. Among the entities of SpA, ankylosing spondylitis has drawn the attention of some researchers, because of its specific mechanism of disease progression. It has been studied earlier that its progression is due to the presence of HLA (human leukocyte antigen) - B27. It shows molecular similarity and immunological cross-reactivity with some of the gut microbiome. Since SpA could be treated or its symptoms could be lessen by medications, but medications itself show many side effects and other complications. Probiotic- being the natural product has been found to be effective against many SpA entities, including Ankylosing Spondylitis. It alters gut microflora somehow in such a way that it helps in reducing the predisposition of any factor to SpA. Here we consider the complex relationship between SpA pathogenesis and gut microbes; with discussion that how use of probiotics as an alternative drug therapy may treat or reduce the progression of SpA, which could be a better future target to treat SpA entities.
脊柱关节病(SpA)或脊椎关节病是指脊柱的任何关节疾病。在脊柱关节病的各种类型中,强直性脊柱炎因其独特的疾病进展机制引起了一些研究人员的关注。早期研究表明,其进展是由于存在人类白细胞抗原(HLA)-B27。它与一些肠道微生物群表现出分子相似性和免疫交叉反应性。由于脊柱关节病可以通过药物治疗或减轻其症状,但药物本身会出现许多副作用和其他并发症。益生菌作为天然产物,已被发现对包括强直性脊柱炎在内的许多脊柱关节病有效。它以某种方式改变肠道微生物群,从而有助于降低任何因素导致脊柱关节病的易感性。在此,我们探讨脊柱关节病发病机制与肠道微生物之间的复杂关系,并讨论如何将益生菌作为替代药物疗法来治疗或减缓脊柱关节病的进展,这可能是未来治疗脊柱关节病的一个更好靶点。